Groundbreaking contract with global ingredient distributor IMCD

HBC has signed a comprehensive distribution contract with IMCD, the global leader in sales, marketing and distribution of speciality chemicals and ingredients.

The distribution agreement is an important next step for HBC towards the global distribution of nutritional and nutraceutical grade products. The IMCD Group has 49,000 customers in 50 countries.

IMCD’s activity is the sales, marketing and distribution of human & pharma grade raw materials through extensive local networks, market intelligence and technical expertise. IMCD’s dedicated team of nutra experts will offer technical advice and formulation support to reformulate HBC products in response to consumer led trends or market demands.

The agreement covers sixteen territories worldwide including the US & Canada, most of South America, including Argentina, Brazil and Mexico, as well as Australia, New Zealand, South Africa and Turkey.

The distribution contract with IMCD follows soon after the granting of a unique set of label claims for ProGo® in North America.

The products included in the distribution agreement are:

  1. ProGo® Bioactive Peptides
  2. CollaGo® Collagen Peptides
  3. CalGo® Collagenic Hydroxyapatite
  4. OmeGo® Unrefined Salmon Oil

Bora Turan, Nutraceuticals Director from IMCD says: “HBC’s sustainable, unique and clinically studied products, as well as their continuous investments in R&D and quality, perfectly complement our existing science-based product portfolio and our vision. With unique selling points and impressive health claims, we are confident that the addition of HBC’s products to our portfolio will incite a lot of interest amongst our customers. IMCD has a long-established business in the Americas as well as the other territories related to this agreement, and our experienced team of Nutra experts have a profound knowledge of the consumer trends that are driving these local markets. With the support of our application labs across the Americas, EMEA and Asia-Pacific, we are looking forward to collaborating with HBC and utilizing their products to formulate trend-based finished concepts that our customers can swiftly launch to market, meeting consumer demands for a multitude of health needs."

Roger Hofseth says: “This is another significant milestone for HBC, to enter into an exclusive agreement with one of the world’s leading nutraceutical and pharmaceutical distributors. This announcement is testament to the investments in R&D and science the company has made over the years. The recently approved health claims are starting to grab the attention of leading players in the healthcare market. IMCD has a phenomenal presence globally, but particularly in North America where we expect them to have success in opening doors for our medical grade nutrition ingredients and we look forward to getting to work immediately.”